MX375431B - Virus de la enfermedad de newcastle y usos de los mismos. - Google Patents

Virus de la enfermedad de newcastle y usos de los mismos.

Info

Publication number
MX375431B
MX375431B MX2015011886A MX2015011886A MX375431B MX 375431 B MX375431 B MX 375431B MX 2015011886 A MX2015011886 A MX 2015011886A MX 2015011886 A MX2015011886 A MX 2015011886A MX 375431 B MX375431 B MX 375431B
Authority
MX
Mexico
Prior art keywords
newcastle disease
viruses
compositions
disease virus
immune cell
Prior art date
Application number
MX2015011886A
Other languages
English (en)
Other versions
MX2015011886A (es
Inventor
Adolfo Garcia-Sastre
Dmitry Zamarin
James Allison
Jedd D Wolchok
Peter Palese
Original Assignee
Icahn School Med Mount Sinai
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Memorial Sloan Kettering Cancer Center filed Critical Icahn School Med Mount Sinai
Publication of MX2015011886A publication Critical patent/MX2015011886A/es
Publication of MX375431B publication Critical patent/MX375431B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen en la presente virus quiméricos de la enfermedad de Newcastle diseñados para expresar un agonista de una señal co-estimuladora de una célula inmune y composiciones que comprenden tales virus. También se describen en la presente virus quiméricos de la enfermedad de Newcastle, diseñados para expresar un antagonista de una señal inhibidora de una célula inmune y composiciones que comprenden tales virus. Los virus quiméricos de la enfermedad de Newcastle y composiciones son útiles en el tratamiento de cáncer. Además, se describen en la presente métodos para tratar el cáncer que comprenden administrar virus de la enfermedad de Newcastle en combinación con un agonista de una señal co-estimuladora de una célula inmune y/o antagonista de una señal inhibidora de una célula inmune.
MX2015011886A 2013-03-14 2014-03-04 Virus de la enfermedad de newcastle y usos de los mismos. MX375431B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361782994P 2013-03-14 2013-03-14
PCT/US2014/020299 WO2014158811A1 (en) 2013-03-14 2014-03-04 Newcastle disease viruses and uses thereof

Publications (2)

Publication Number Publication Date
MX2015011886A MX2015011886A (es) 2016-05-31
MX375431B true MX375431B (es) 2025-03-06

Family

ID=51527979

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015011886A MX375431B (es) 2013-03-14 2014-03-04 Virus de la enfermedad de newcastle y usos de los mismos.
MX2019008086A MX2019008086A (es) 2013-03-14 2015-09-08 Virus de la enfermedad de newcastle y uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2019008086A MX2019008086A (es) 2013-03-14 2015-09-08 Virus de la enfermedad de newcastle y uso de los mismos.

Country Status (28)

Country Link
US (5) US20160015760A1 (es)
EP (1) EP2968525A4 (es)
JP (4) JP6596411B2 (es)
KR (1) KR102222157B1 (es)
CN (3) CN111218429A (es)
AP (1) AP2015008685A0 (es)
AU (2) AU2014241843B2 (es)
BR (1) BR112015021414B1 (es)
CA (1) CA2905272A1 (es)
CL (2) CL2015002532A1 (es)
CR (1) CR20150465A (es)
DO (1) DOP2015000227A (es)
EA (1) EA038981B1 (es)
GE (2) GEP20196976B (es)
HK (1) HK1216618A1 (es)
IL (2) IL241120A0 (es)
MA (1) MA38406B1 (es)
MD (1) MD4655C1 (es)
MX (2) MX375431B (es)
MY (1) MY180687A (es)
NI (1) NI201500131A (es)
NZ (1) NZ711946A (es)
PE (1) PE20151921A1 (es)
PH (1) PH12015502087A1 (es)
SG (2) SG11201507412SA (es)
TN (1) TN2015000353A1 (es)
WO (1) WO2014158811A1 (es)
ZA (1) ZA201506192B (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
KR102310692B1 (ko) * 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
MY181834A (en) 2014-07-21 2021-01-08 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016065330A1 (en) * 2014-10-24 2016-04-28 Aladar Szalay Combination immunotherapy approach for treatment of cancer
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
JP6692834B2 (ja) 2015-02-09 2020-05-13 スリングショット バイオサイエンシーズ， インコーポレイテッド 調整可能な光学特性を有するヒドロゲル粒子およびその使用の方法
CN105985966B (zh) * 2015-03-06 2024-08-16 普莱柯生物工程股份有限公司 基因vii型新城疫病毒株、其疫苗组合物、制备方法及应用
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
PT3393504T (pt) 2015-12-22 2025-12-30 Novartis Ag Recetor de antigénio quimérico (car) de mesotelina e anticorpo contra o inibidor de pd-l1 para utilização combinada em terapia anticancerígena
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
CA3016287A1 (en) 2016-03-04 2017-09-08 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
GB201700350D0 (en) 2017-01-09 2017-02-22 Replimune Ltd Altered virus
US20200024351A1 (en) 2017-04-03 2020-01-23 Jounce Therapeutics, Inc. Compositions and Methods for the Treatment of Cancer
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
JOP20190256A1 (ar) * 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
BR112019024656A2 (pt) 2017-05-25 2020-06-09 Univ Central Florida Res Found Inc vírus oncolíticos para a sensibilização de células tumorais para morte por células exterminadoras naturais
AU2019215031C1 (en) 2018-01-31 2026-02-26 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019227003A1 (en) 2018-05-25 2019-11-28 Novartis Ag Combination therapy with chimeric antigen receptor (car) therapies
AU2019284911B2 (en) 2018-06-13 2026-04-09 Novartis Ag BCMA chimeric antigen receptors and uses thereof
JP2021530501A (ja) * 2018-07-13 2021-11-11 アイカーン スクール オブ メディシン アット マウント サイナイ 癌の治療のためのａｐｍｖ及びその使用
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
AU2019327493A1 (en) * 2018-08-29 2021-03-04 Shattuck Labs, Inc. Combination therapies comprising sirp alpha-based chimeric proteins
US20210347851A1 (en) 2018-09-28 2021-11-11 Novartis Ag Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
WO2020069405A1 (en) 2018-09-28 2020-04-02 Novartis Ag Cd22 chimeric antigen receptor (car) therapies
US20210379129A1 (en) * 2018-10-09 2021-12-09 Biocomo Incorporation Anticancer agent, pharmaceutical composition for cancer treatment, and kit
CN109627336A (zh) * 2018-12-20 2019-04-16 南京昂科利医药科技创新研究院有限公司 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用
EP3917552A1 (en) * 2019-01-29 2021-12-08 Arno Thaller Recombinant oncolytic newcastle disease viruses with increased activity
US20220135682A1 (en) 2019-03-11 2022-05-05 Jounce Therapeutics, Inc. Anti-ICOS Antibodies for the Treatment of Cancer
CA3134144A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Llc Ex vivo methods for producing a t cell therapeutic and related compositions and methods
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CN110564766A (zh) * 2019-09-20 2019-12-13 华农（肇庆）生物产业技术研究院有限公司 一种全基因组表达载体pBR322-DHN3的制备方法
CN110672844A (zh) * 2019-10-29 2020-01-10 华中科技大学 一种新城疫病毒抗体磁免疫化学发光检测试剂盒及其应用
EP4055052A1 (en) 2019-11-05 2022-09-14 Jounce Therapeutics, Inc. Methods of treating cancer with anti-pd-1 antibodies
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
WO2021174208A1 (en) 2020-02-27 2021-09-02 Myst Therapeutics, Llc Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
WO2021229270A1 (es) 2020-05-13 2021-11-18 Laboratorio Avi-Mex, S.A. De C.V. Vacuna recombinante contra covid-19 en vector viral
US20210386804A1 (en) * 2020-06-11 2021-12-16 Tibor Bakács Combination of viral superinfection therapy with subthreshold doses of nivolumab plus ipilimumab in chronic HBV patients
EP4215214A4 (en) * 2020-09-16 2024-07-03 Osaka University THERAPEUTIC AGENT AGAINST CANCER, IMMUNOSTIMULANT AND SCREENING METHOD FOR ANTI-CANCER SUBSTANCE
MX2023005609A (es) 2020-11-13 2023-05-29 Novartis Ag Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
CN115197949A (zh) * 2021-04-13 2022-10-18 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒rNDV-OX40L、其基因组、制备方法及其用途
TW202307210A (zh) 2021-06-01 2023-02-16 瑞士商諾華公司 Ｃｄ１９和ｃｄ２２嵌合抗原受體及其用途
KR102476901B1 (ko) * 2021-08-06 2022-12-14 리벤텍 주식회사 대장암 세포 특이적 감염 뉴캐슬병 바이러스를 이용한 대장암 치료용 암용해성 바이러스 및 이를 이용한 대장암 치료용 조성물
EP4423250A1 (en) 2021-10-29 2024-09-04 Slingshot Biosciences, Inc. Hydrogel particles as feeder cells and as synthetic antigen presenting cells
WO2023215886A1 (en) 2022-05-05 2023-11-09 Slingshot Biosciences, Inc. Engineered particles as red blood cell mimics and compositions containing same for hematology
CN120712108A (zh) 2022-10-26 2025-09-26 弹弓生物科学公司 具有可调整光学性质的大小可调整合成颗粒和用于使用其进行免疫细胞激活的方法
CN121986254A (zh) 2023-08-29 2026-05-05 弹弓生物科学公司 Cd34干细胞模拟物
KR20250083186A (ko) * 2023-11-29 2025-06-09 주식회사 카브 재조합 뉴캣슬병 바이러스 벡터를 포함하는 암 치료용 약제학적 조성물

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3922444A1 (de) 1988-03-01 1991-01-10 Deutsches Krebsforsch Virusmodifizierte tumorvakzine fuer die immuntherapie von tumormetastasen
DE3806565A1 (de) 1988-03-01 1989-09-14 Deutsches Krebsforsch Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5786199A (en) 1989-08-28 1998-07-28 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
PT696326E (pt) 1993-04-30 2003-08-29 Wellstat Biologics Corp Utilizacao de ndv no fabrico de um medicamento para tratamento do cancro
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US5891680A (en) 1995-02-08 1999-04-06 Whitehead Institute For Biomedical Research Bioactive fusion proteins comprising the p35 and p40 subunits of IL-12
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
ATE181112T1 (de) 1995-08-09 1999-06-15 Schweiz Serum & Impfinst Dem genom von minussträngigen rna-viren entsprechende cdna und verfahren zur herstellung von infektiösen minussträngigen rna-viren
CA2230033C (en) 1995-09-27 2010-01-26 Peter L. Collins Production of infectious respiratory syncytial virus from cloned nucleotide sequences
CA2231603C (en) 1995-10-17 2009-04-21 Wayne State University Chicken interleukin-15 and uses thereof
EP0912724B1 (en) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences
BR9712138A (pt) 1996-09-27 2000-01-18 American Cyanamid Co Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
ES2287977T3 (es) 1997-07-11 2007-12-16 Yale University Rabdovirus con cubiertas rediseñadas.
JP2001517448A (ja) 1997-09-19 2001-10-09 アメリカン・サイアナミド・カンパニー 弱毒化呼吸合胞体ウイルス
NZ503664A (en) 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
JP4837827B2 (ja) 1998-06-12 2011-12-14 マウント シナイ スクール オブ メディシン 新規なウイルス増殖方法およびそのためのインターフェロン欠損培養基
EP0974660A1 (en) 1998-06-19 2000-01-26 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Newcastle disease virus infectious clones, vaccines and diagnostic assays
US6544785B1 (en) 1998-09-14 2003-04-08 Mount Sinai School Of Medicine Of New York University Helper-free rescue of recombinant negative strand RNA viruses
US6146642A (en) 1998-09-14 2000-11-14 Mount Sinai School Of Medicine, Of The City University Of New York Recombinant new castle disease virus RNA expression systems and vaccines
US7052685B1 (en) 1998-10-15 2006-05-30 Trustees Of The University Of Pennsylvania Methods for treatment of cutaneous T-cell lymphoma
NZ550861A (en) 1999-04-15 2009-03-31 Wellstat Biologics Corp Treatment of neoplasms with viruses
US20030224017A1 (en) 2002-03-06 2003-12-04 Samal Siba K. Recombinant Newcastle disease viruses useful as vaccines or vaccine vectors
US7244558B1 (en) 1999-05-05 2007-07-17 University Of Maryland Production of novel Newcastle disease virus strains from cDNAs and improved live attenuated Newcastle disease vaccines
DE122007000070I1 (de) 1999-07-14 2008-01-31 Sinai School Medicine In Vitro-rekonstitution von segmentierten Negativstrang-Rna-Viren
AU7607900A (en) 1999-09-22 2001-04-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
US6896881B1 (en) 1999-09-24 2005-05-24 Mayo Foundation For Medical Education And Research Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family
EP1248654B1 (en) 2000-01-20 2005-10-05 Universität Zürich Institut für Medizinische Virologie Intra-tumoral administration of il-12 encoding naked nucleic acid molecules
WO2001077394A1 (en) 2000-04-10 2001-10-18 Mount Sinai School Of Medicine Of New York University Screening methods for identifying viral proteins with interferon antagonizing functions and potential antiviral agents
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
FR2823222B1 (fr) 2001-04-06 2004-02-06 Merial Sas Vaccin contre le virus de la fievre du nil
WO2002102404A1 (en) 2001-06-18 2002-12-27 Institut National De La Recherche Agronomique Uses of cytokines
WO2003092579A2 (en) 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
WO2003102183A1 (en) 2002-06-03 2003-12-11 Dnavec Research Inc. Pramyxovirus vectors encoding antibody and utilization thereof
US7971030B2 (en) 2002-08-07 2011-06-28 Mmagix Technology Limited Method for using multiple processing resources which share multiple co-processor resources
SE0203159D0 (sv) 2002-10-25 2002-10-25 Electrolux Ab Handtag till ett motordrivet handhållet verktyg
US9068234B2 (en) 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
EP2292246A1 (en) 2004-11-12 2011-03-09 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
PL1899364T5 (pl) 2005-05-17 2024-12-09 University Of Connecticut Kompozycje i sposoby immunomodulacji w organizmie
WO2007008918A2 (en) 2005-07-08 2007-01-18 Wayne State University Virus vaccines comprising envelope-bound immunomodulatory proteins and methods of use thereof
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
JP2007120880A (ja) 2005-10-28 2007-05-17 Mitsubishi Electric Corp クロスフローファン
MX2008007056A (es) 2005-12-02 2008-11-12 Sinai School Medicine Virus quimericos que presentan proteinas de superficie no nativas y usos de los mismos.
EP1984505B1 (en) 2006-01-13 2019-12-25 The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US20090175826A1 (en) 2006-06-05 2009-07-09 Elankumaran Subbiah Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008011726A1 (en) 2006-07-27 2008-01-31 Ottawa Health Research Institute Staged immune-response modulation in oncolytic therapy
EP3293266B1 (en) 2007-05-04 2025-12-24 University Health Network Il-12 immunotherapy for cancer
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
CA2691785C (en) 2007-06-27 2017-01-10 Marine Polymer Technologies Inc. Complexes of il-15 and il-15ralpha and uses thereof
EP2085092A1 (en) * 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Attenuated oncolytic paramyxoviruses encoding avian cytokines
US8313896B2 (en) * 2008-04-04 2012-11-20 The General Hospital Corporation Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
WO2010042433A1 (en) * 2008-10-06 2010-04-15 Bristol-Myers Squibb Company Combination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
CN101787373B (zh) 2009-01-23 2013-06-19 中国人民解放军第二军医大学东方肝胆外科医院 一种携带外源基因在包装细胞中高效生产的重组病毒载体、其构建方法及其用途
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
AU2010241864B2 (en) 2009-04-30 2014-02-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Inducible interleukin-12
US20100297072A1 (en) 2009-05-19 2010-11-25 Depinho Ronald A Combinations of Immunostimulatory Agents, Oncolytic Virus, and Additional Anticancer Therapy
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
CN105331633A (zh) 2009-08-21 2016-02-17 梅里亚有限公司 重组禽副粘病毒疫苗及其制备和使用方法
CN104826106B (zh) 2009-09-30 2019-01-11 斯隆凯特林防癌纪念中心 用于治疗癌症的组合免疫疗法
US10238734B2 (en) 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
WO2012000188A1 (en) 2010-06-30 2012-01-05 Tot Shanghai Rd Center Co., Ltd. Recombinant tumor vaccine and method of producing such
EP2619229B1 (en) 2010-09-21 2016-04-06 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US20120082687A1 (en) * 2010-10-04 2012-04-05 Alex Wah Hin Yeung Use of cell adhesion inhibitor for the mobilization of antigen presenting cells and immune cells in a cell mixture (AIM) from the peripheral blood and methods of use
CN114262690A (zh) 2011-04-15 2022-04-01 吉恩勒克斯公司 减毒的痘苗病毒的克隆毒株及其使用方法
EP2537933A1 (en) 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
CA2850575C (en) 2011-10-11 2020-12-15 Universitat Zurich Prorektorat Mnw Combination medicament comprising il-12 and an agent for blockade of t-cell inhibitory molecules for tumour therapy
DK2806883T3 (da) 2012-01-25 2019-07-22 Dnatrix Inc Biomarkører og kombinationsterapier under anvendelse af onkolytisk virus og immunomodulation
EP2669381A1 (en) 2012-05-30 2013-12-04 AmVac AG Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein
US20150250837A1 (en) 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
WO2014066527A2 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
KR102222157B1 (ko) 2013-03-14 2021-03-03 이칸 스쿨 오브 메디슨 엣 마운트 시나이 뉴캐슬병 바이러스 및 이의 용도
KR102539359B1 (ko) 2013-04-19 2023-06-02 싸이튠 파마 감소된 혈관 누출 증후군에 대한 사이토카인 유도체 치료
SI3030262T1 (sl) 2013-08-08 2020-03-31 Cytune Pharma Kombiniran farmacevtski sestavek
CA2919725C (en) 2013-08-08 2023-04-18 Cytune Pharma An il-15 and il-15r.aplha. sushi domain based modulokines
KR102310692B1 (ko) 2013-09-03 2021-10-12 메디뮨 리미티드 약독화된 뉴캐슬병 바이러스를 특징으로 하는 조성물 및 신생물을 치료하기 위한 사용 방법
WO2015127501A1 (en) 2014-02-27 2015-09-03 Viralytics Limited Combination method for treatment of cancer
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
WO2016018920A1 (en) 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2016048903A1 (en) 2014-09-22 2016-03-31 Intrexon Corporation Improved therapeutic control of heterodimeric and single chain forms of interleukin-12
EP3230498B1 (en) 2014-12-09 2023-01-18 Merck Sharp & Dohme LLC System and methods for deriving gene signature biomarkers of response to pd-1 antagonists
CN106166294A (zh) 2015-05-18 2016-11-30 国科丹蓝生物科技（北京）有限公司 一种用于术前介入放疗治疗肿瘤的化合物
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
SG11201803546WA (en) 2015-11-09 2018-05-30 Immune Design Corp Compositions comprising lentiviral vectors expressing il-12 and methods of use thereof
WO2017118866A1 (en) 2016-01-08 2017-07-13 Replimune Limited Engineered virus
TWI911597B (zh) 2016-01-15 2026-01-11 美商Ｒｆｅｍｂ控股有限公司 癌症之免疫治療
US10344067B2 (en) 2016-02-25 2019-07-09 Deutsches Krebsforschungszentrum RNA viruses expressing IL-12 for immunovirotherapy
CN105734023B (zh) 2016-03-28 2019-04-26 江苏康缘瑞翱生物医药科技有限公司 一种重组新城疫病毒在制备抗肝癌药物中的应用
ES2904882T3 (es) 2016-04-29 2022-04-06 Virogin Biotech Canada Ltd Vectores de HSV con replicación mejorada en células cancerosas

Also Published As

Publication number Publication date
PE20151921A1 (es) 2015-12-26
CN105188746A (zh) 2015-12-23
KR20150127164A (ko) 2015-11-16
NZ711946A (en) 2020-05-29
IL264385B (en) 2021-09-30
JP2018198621A (ja) 2018-12-20
MA38406A1 (fr) 2017-12-29
MD4655C1 (ro) 2020-06-30
JP2023002553A (ja) 2023-01-10
GEAP201913952A (en) 2019-02-11
US10251922B2 (en) 2019-04-09
ZA201506192B (en) 2021-01-27
MD20150100A2 (ro) 2016-02-29
CA2905272A1 (en) 2014-10-02
PH12015502087B1 (en) 2016-01-18
SG11201507412SA (en) 2015-10-29
WO2014158811A8 (en) 2015-09-17
DOP2015000227A (es) 2015-11-15
CR20150465A (es) 2016-01-25
US20180280455A1 (en) 2018-10-04
CL2015002532A1 (es) 2016-07-15
CN105188746B (zh) 2020-03-17
CL2018000515A1 (es) 2018-08-03
MY180687A (en) 2020-12-07
MX2019008086A (es) 2019-09-10
JP6596411B2 (ja) 2019-10-23
EA038981B1 (ru) 2021-11-17
US20180256655A1 (en) 2018-09-13
NI201500131A (es) 2015-10-19
AU2014241843B2 (en) 2019-05-02
AU2019206040A1 (en) 2019-08-01
BR112015021414A2 (pt) 2017-07-18
KR102222157B1 (ko) 2021-03-03
US20180078592A1 (en) 2018-03-22
SG10201802982WA (en) 2018-06-28
CN111172120A (zh) 2020-05-19
MD4655B1 (ro) 2019-11-30
TN2015000353A1 (en) 2017-01-03
IL264385A (en) 2019-02-28
US20140271677A1 (en) 2014-09-18
IL241120A0 (en) 2015-11-30
GEP20196976B (en) 2019-06-10
JP2020202850A (ja) 2020-12-24
MA38406B1 (fr) 2020-03-31
HK1216618A1 (zh) 2016-11-25
EP2968525A1 (en) 2016-01-20
BR112015021414B1 (pt) 2020-11-10
AP2015008685A0 (en) 2015-08-31
PH12015502087A1 (en) 2016-01-18
EP2968525A4 (en) 2016-10-26
AU2014241843A1 (en) 2015-09-10
EA201591740A1 (ru) 2016-06-30
MX2015011886A (es) 2016-05-31
WO2014158811A1 (en) 2014-10-02
CN111218429A (zh) 2020-06-02
US20160015760A1 (en) 2016-01-21
JP2016517269A (ja) 2016-06-16

Similar Documents

Publication Publication Date Title
CL2018000515A1 (es) Virus de la enfermedad de newcastle y usos de los mismos (divisional sol. 2532-2015)
JOP20200192A1 (ar) أجسام مضادة لـ tigit
MX385585B (es) Anticuerpos anti-c10orf54 y usos de los mismos.
CL2018000353A1 (es) Agentes inductores de la apoptosis para tratar el cáncer y enfermedades inmunes y autoinmunes
EA202090547A2 (ru) Макроциклические деаза-оксипурины для лечения вирусных инфекций
EA201992133A1 (ru) Производные пиперидино-пиримидина для лечения вирусных инфекций
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
CL2016000805A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201590931A1 (ru) Гетероциклические замещенные производные 2-амино-хиназолина для лечения вирусных инфекций
MX2015007888A (es) Compuestos antivirales.
CL2015000784A1 (es) Compuestos derivados de acilaminopirimidina, inductores de interferon; composicion farmaceutica que los comprende; su uso en el tratamiento de infecciones viricas, trastornos inmunitarios, cancer y otras enfermedades.
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201592269A1 (ru) Способы и композиции для снижения иммуносупрессии опухолевыми клетками
HRP20180639T1 (hr) Derivati izoindolina, namijenjeni upotrebi u liječenju virusne infekcije
UY34420A (es) ?métodos de tratamiento del virus de la hepatitis c con que de gs-7977 y ribavirina, composiciones y usos"
MX393281B (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
EA201592242A1 (ru) Производные пиридона для лечения вирусных инфекций и других заболеваний
UY35390A (es) Compuestos con actividad anti-hcv y composiciones farmacéuticas que los contienen
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
EA201790771A1 (ru) Фармацевтические композиции длительного действия для лечения гепатита c
MX2016012104A (es) Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.
MX2016004961A (es) Procedimientos y composiciones para el tratamiento de infecciones por s. equi.
TH148307A (th) การรักษาการติดเชื้อไวรัสตับอักเสบ c โดยใช้อะลิสพอริเวียร์

Legal Events

Date Code Title Description
FG Grant or registration